Stuttgart - Delayed Quote EUR

ABIONYX Pharma SA (609.SG)

1.2200

+0.0040

+(0.33%)

At close: January 10 at 3:37:14 PM GMT+1

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS, January 08, 2025--Regulatory News: ABIONYX Pharma (Paris:ABNX):

Business Wire 3 days ago

ABNX.PA
ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024

TOULOUSE, France & LAKELAND, Mich., November 29, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting on November 28th, 2024, were approved.

Business Wire last month

ABNX.PA
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024

TOULOUSE, France & LAKELAND, Mich., November 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the recombinant human apolipoprotein apoA-I, today provides an update on its business and its cash position as of September 30, 2024.

Business Wire last month

ABNX.PA
ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents

TOULOUSE, France & LAKELAND, Mich., November 07, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today informs its shareholders that its Combined General Meeting (Ordinary and Extraordinary) will be held on November 28, 2024 at 2 pm at the Company's head office at 33-43 avenue Georges Pompidou Bât. D - 31130

Business Wire 2 months ago

ABNX.PA
ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"

TOULOUSE, France & LAKELAND, Mich., October 24, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced that the Company’s Phase 2b RACERS study in sepsis has been selected again as a poster presentation in the "AKI: Clinical, Outcome, and Trials- Epidemiology and Pathophysiology" poster session at t

Business Wire 2 months ago

ABNX.PA
ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency

TOULOUSE, France & LAKELAND, Mich., October 21, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, has submitted on July 11, 2024, a formal Application for scientific advice to the European Medicines Agency (EMA) for recombinant human apolipoprotein A-I, CER-001, for treatment of lecithin-cholesterol acyltransferas

Business Wire 2 months ago

ABNX.PA
ABIONYX Pharma Announces Its 2024 Half-Year Financial Results

TOULOUSE, FRANCE & LAKELAND, Mich., September 26, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only recombinant apoA-1, today announces its financial results for the first half of 2024.

Business Wire 3 months ago

ABNX.PA
ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024

TOULOUSE, France & LAKELAND, Mich., August 22, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announced today its cash position for the 1st half to June 30, 2024, and the highlights of the period.

Business Wire 4 months ago

ABNX.PA
ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million

TOULOUSE, France & LAKELAND, Mich., July 01, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the success of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number

Business Wire 6 months ago

ABNX.PA
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting

TOULOUSE, France & LAKELAND, Mich., June 27, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that all resolutions presented at its Combined General Meeting were unanimously approved.

Business Wire 6 months ago

ABNX.PA
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million

TOULOUSE, France & LAKELAND, Mich., June 19, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces the launch of a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons for an amount of close to €3.4 million through the issue of a maximum number o

Business Wire 6 months ago

ABNX.PA
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

TOULOUSE, France & LAKELAND, Mich., June 13, 2024--ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced that the company has completed a pre-IND (Investigational New Drug Application, IND) meeting with the US Food and Drug Administration and has received feedback to support an IND filing for its candidate drug. This is

Business Wire 6 months ago

ABNX.PA
ABIONYX: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS, June 04, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):

Business Wire 7 months ago

ABNX.PA
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024

TOULOUSE, France, LAKELAND, Mich., May 16, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of March 31, 2024.

Business Wire 7 months ago

ABNX.PA
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023

TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.

Business Wire 8 months ago

ABNX.PA
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant

TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.

Business Wire 9 months ago

ABNX.PA
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results

TOULOUSE, France & LAKELAND, Mich., March 11, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced its 2023 full-year financial results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated financial statements have been completed. T

Business Wire 9 months ago

ABNX.PA
ABIONYX Pharma announces its financial calendar for the year 2024

TOULOUSE, France & LAKELAND, Mich., March 07, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2024.

Business Wire 10 months ago

ABNX.PA
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 4th Quarter 2023

TOULOUSE, France & LAKELAND, Mich., February 29, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today provides an update on its activity and cash position as of December 31, 2023.

Business Wire 10 months ago

ABNX.PA
ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112

TOULOUSE, France, LAKELAND Mich., February 16, 2024--Regulatory News: Following numerous calls received since the press release of February 15, 2024, ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME) (Paris:ABNX), intends to clarify that the Phase 3 clinical results for CSL112 are extremely positive for the company's development and future.

Business Wire 10 months ago

ABNX.PA

Performance Overview

Return	609.SG	CAC 40
YTD	+4.99%	+1.61%
1-Year	-3.48%	+0.06%
3-Year	-56.81%	+2.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ABIONYX Pharma SA (609.SG)

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024

ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024

ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"

ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency

ABIONYX Pharma Announces Its 2024 Half-Year Financial Results

ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024

ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million

ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting

ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million

ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024

ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023

ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant

ABIONYX Pharma Announces Its 2023 Full-Year Financial Results

ABIONYX Pharma announces its financial calendar for the year 2024

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 4th Quarter 2023

ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112

Performance Overview